Originally focused on novel cancer therapies including CDK9 and mitochondrial pathway inhibitors, MEI Pharma underwent a strategic transformation in 2025. The company now emphasizes crypto treasury strategy with guidance from Litecoin creator Charlie Lee while evaluating continued development of voruciclib and zandelisib.
Cyborg Score Rationale
MEI Pharma faces significant headwinds: micro-cap status ($100.8M market cap), minimal cash runway (~6.7 months as of June 2026), and a controversial strategic pivot away from core pharma operations. The dramatic rebranding and shift to crypto treasury strategy introduces substantial business risk and execution uncertainty.
Top Insights
(September 2025) Company rebranded to Lite Strategy, Inc., shifting strategy from oncology focus to Litecoin treasury management with $110.4 million in LTC holdings
(September 2025) Litecoin creator Charlie Lee joined board to guide digital asset treasury strategy
Oncology pipeline remains in portfolio including voruciclib (CDK9 inhibitor) and zandelisib (PI3K delta inhibitor) under continued evaluation
Severe capital constraints with only ~6.7 months cash runway and monthly burn of $3.05 million as of June 2026
Named Competitors
Oncology Pipeline Competitors (Historical) — Metabolic and cancer therapeutics
Targeted Cancer Therapies — Epigenetic cancer drug development
Recent Developments
(September 2025) Rebranded to Lite Strategy, Inc., ticker changed to LITS
(2025) Acquired 929,548 Litecoin tokens at average price of $107.58, establishing $110.4 million LTC treasury
(June 2026) Stock trading at ~$2.84-3.07 with micro-cap valuation of $100.8 million
Open the full interactive MEI Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.